NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis $3.14 +0.01 (+0.16%) As of 10:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Addex Therapeutics Stock (NASDAQ:ADXN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Addex Therapeutics alerts:Sign Up Key Stats Today's Range$3.02▼$3.2350-Day Range$2.76▼$5.9552-Week Range$2.56▼$11.97Volume4,487 shsAverage Volume57,518 shsMarket Capitalization$3.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company develops small-molecule medicines that act through allosteric modulation, a drug-discovery approach designed to influence G protein-coupled receptors (GPCRs) at sites distinct from where naturally occurring signaling molecules bind. Addex’s research has focused primarily on treatments for disorders of the central nervous system. Its development programs have included ADX71149, an investigational positive allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), and other compounds targeting neurological and psychiatric conditions. The company has also investigated allosteric modulators of mGluR5 and the GABA-B receptor for potential applications including epilepsy, pain, addiction and other brain disorders. Founded in 2002, Addex has advanced its programs through internal research and collaborations with pharmaceutical and biotechnology companies. Its activities are centered in Switzerland, while its clinical development and commercial opportunities are international in scope. As a clinical-stage company, Addex’s product candidates remain subject to clinical testing and regulatory review and are not necessarily approved for commercial use.AI Generated. May Contain Errors. Read More Addex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreADXN MarketRank™: Addex Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAddex Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAddex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Addex Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Addex Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently decreased by 93.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Addex Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions16.14% of the stock of Addex Therapeutics is held by institutions.Read more about Addex Therapeutics' insider trading history. Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADXN Stock News HeadlinesAddex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaOctober 8 at 1:00 AM | globenewswire.comAddex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For NeurosterixOctober 2, 2026 | rttnews.comOminous New Day in America (Get Ready for it)A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S&L collapse and Black Monday crash, and the 2000s dot-com bust and Lehman Brothers collapse - says a major shift is coming to how Americans bank, work and insure themselves. The New York Times has credited him as the first to spot looming dangers, and he has testified before Congress on past financial crises.October 8 at 1:00 AM | Weiss Ratings (Ad)Critical Comparison: Kiora Pharmaceuticals (NASDAQ:KPRX) versus Addex Therapeutics (NASDAQ:ADXN)October 2, 2026 | americanbankingnews.comAddex Therapeutics Announces Executive Management ChangesOctober 2, 2026 | globenewswire.comFinancial Contrast: Addex Therapeutics (NASDAQ:ADXN) and Eloxx Pharmaceuticals (NASDAQ:ELOX)September 30, 2026 | americanbankingnews.comWhat Addex Therapeutics (ADXN) Said on Its Q2 Earnings CallSeptember 30, 2026 | americanbankingnews.comAddex (ADXN) Q2 2026 Earnings Call TranscriptSeptember 29, 2026 | finance.yahoo.comSee More Headlines ADXN Stock Analysis - Frequently Asked Questions How have ADXN shares performed this year? Addex Therapeutics' stock was trading at $7.72 at the beginning of 2026. Since then, ADXN stock has decreased by 59.4% and is now trading at $3.1350. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) posted its quarterly earnings results on Friday, September, 25th. The company reported ($1.48) EPS for the quarter. The business earned $0.01 million during the quarter. Read the conference call transcript. When did Addex Therapeutics' stock split? Shares of Addex Therapeutics reverse split on Monday, October 23rd 2023.The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Addex Therapeutics IPO? Addex Therapeutics (ADXN) raised $0 in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,925,532 shares at a price of $0.00 per share. How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL). Company Calendar Last Earnings9/25/2026Today10/08/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (26m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ADXN's financial health is in the Red zone, according to TradeSmith. ADXN has been in this zone for over 26 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ADXN CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees3Year Founded2002Profitability EPS (Trailing Twelve Months)($5.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.12 million Net MarginsN/A Pretax Margin-18,763.55% Return on Equity-174.44% Return on Assets-126.47% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$210 thousand Price / Sales18.90 Cash FlowN/A Price / Cash FlowN/A Book Value$4.67 per share Price / Book0.69Miscellaneous Outstanding Shares1,230,000Free Float1,047,000Market Cap$3.97 million OptionableNot Optionable Beta1.52 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ADXN) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersHOST Just Entered the AI Data Center Race in a BIG WayHost Digital Inc (NYSE American: HOST) has completed its merger with Healthy Choice Wellness Corp as of Septem...Trading Wire | SponsoredOminous New Day in America (Get Ready for it)A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S...Weiss Ratings | SponsoredA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | Sponsored$169 Private Jet Trick ExposedFor $169, a growing circle of travelers are booking private jets without the wait, the hassle, or the high pri...International Living | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
